Overweight with 3-tranche scale-in at 25-30%/40%/45% targets, $360 hard stop, mandatory 5-10% put hedge
Overweight is the correct rating because it honors the 10/01 reflection against a third consecutive Hold (which produced -3.1% alpha), respects the fortress-balance-sheet floor (9/1 reflection forbidding exits on quality compounders at drawdown), and maintains meaningful directional exposure while the 25-30% T1 sizing and $360 stop acknowledge the 1.465-beta amplification risk and binary event timing that the Neutral and conservative analysts correctly flagged. The asymmetry of payoff — involved exposure capturing 6-12 month re-rating while hedging the 3-week binary event — respects both asymmetries simultaneously.
| Position | Action |
|---|---|
| Tranche 1 entry (~392) | 25-30% of target position |
| Tranche 2 entry (close >$414, volume >3.5M) | 40% of target position |
| Tranche 3 entry (close >$447, volume >4M) | 45% of target position |
| 5-10% put spread hedge | $370/$320 put spread, 75-90 DTE |
| Bullish Q3 print (2 of 3: inventory divergence narrowing, Ion reacceleration, guidance reaffirm/raise) | Upgrade to Buy, accelerate to full target, price target $470-500 |
| In-line Q3 print | Maintain Overweight, await T2/T3 triggers |
| Bearish Q3 print (2 of 3: divergence widening, Ion deceleration, downward guidance OR material Hugo commentary) | Downgrade to Hold, trim 20-25% |
ISRG represents a generational buying opportunity with 39% forward EPS growth, a razor-and-blade moat generating $7.36B in high-margin recurring revenue, and an asymmetric risk/reward profile of 1:5 to the 52-week high versus 1:1 to the 200-day moving average.
| Indicator | Value | Signal |
|---|---|---|
| 10 EMA | $399.28 | bearish |
| 50 SMA | $380.04 | neutral |
| 200 SMA | $447.22 | bearish |
| MACD | 7.45 | neutral |
| MACD Signal | 6.59 | neutral |
| MACD Histogram | 0.86 | bearish |
| RSI | 51.21 | neutral |
| Bollinger Upper Band | $426.47 | bearish |
| Bollinger Middle Band | $387.37 | neutral |
| Bollinger Lower Band | $348.28 | bullish |
| ATR | 11.26 |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: ~392 current price
Then: Deploy 25-30% of target position
Forward P/E of 32.4x represents a discount on a PEG basis for a company growing 3.7x faster than the market
↩ rebuts: “Bear's 'premium valuation' argument ignores that 39% forward EPS growth hasn't been priced in yet, representing future re-rating opportunity rather than past appreciation.”
EV: +54% · concedes: Forward P/E of 32.4x is a premium multiple that requires continued execution; 200 SMA at $447 represents a near-term technical resistance level; Macro uncertainty (Iran-inflation tail risk) exists, though priced as a tail scenario; Zero news flow cited by bear could signal lack of near-term catalysts beyond earnings
ISRG's 35% decline has not yet brought the valuation to fair value; the stock remains dangerously priced at 45x TTM P/E with deteriorating technical momentum, decelerating fundamentals signaled by inventory growth outpacing revenue, and multiple macro/competitive headwinds that could push the stock to $280-$328 on any earnings disappointment or rate shock.
EV: +18% (probability-weighted, 6-12 months) · concedes: ISRG does have a fortress balance sheet with $5.22B in cash and zero long-term debt; The 17.4% ROE is good quality; Da Vinci 5 early adoption is real and represents future growth potential; The moat from installed base is significant; The stock has already declined 35% from highs
→ vs conservative: Waiting for 200 SMA reclaim at $447 compresses reward-to-risk ratio and sacrifices the catalyst window; buying after a 15% rally kills R/R rather than buying at $392
→ vs conservative: Forward P/E of 32.4x with 39% EPS growth yields PEG well under 1.0, not the stretched 1.87 trailing PEG cited; this is a high-quality compounder growing into its valuation
→ vs conservative: HOLD into Q3 risks missing a potential 35% drawdown reversal; inaction is the actual danger in this setup
→ vs neutral: Zero news flow and low confidence is a bull case, not uncertainty; no negative catalysts, no retail froth to unwind, path of least resistance is up
→ vs neutral: Q3 earnings is a known catalyst already accounted for in the 40% sizing and put spread hedge; scale-in approach harvests binary events without betting the farm
| neutral |
Support: 348.28 · 365 · 380 | Resistance: 414 · 417 · 447 · 492
ISRG exhibits a bearish long-term structure (price 12.4% below 200 SMA) with mixed short/medium-term signals. Key support at 50 SMA ($380) and BOLL middle ($387.37) must hold; failure opens downside to $348. Resistance at $414-$417 (recent rally high) must be reclaimed for any sustained recovery.
Market Capitalization
$140.4B
Trailing P/E Ratio
45.0x
Forward P/E Ratio
32.4x
PEG Ratio
1.87
Price / Book
7.63x
EPS (TTM)
$8.71
Forward EPS
$12.09
52-Week High
$603.88
52-Week Low
$328.57
50-Day Moving Average
$378.84
200-Day Moving Average
$448.05
Beta
1.465
Revenue Q2'26 (2026-06)
$2.892B
Gross Profit Q2'26
$1.960B
Operating Income Q2'26
$971.9M
Net Income Q2'26
$818.1M
Diluted EPS Q2'26
$2.29
Revenue YoY Growth (Q2'26)
+18.5%
Gross Margin Q2'26
67.8%
Operating Margin
33.6%
R&D (Q2'26)
$370.6M
SG&A (Q2'26)
$617.9M
Revenue (TTM)
$11.03B
Gross Profit (TTM)
$7.36B
EBITDA (TTM)
$4.18B
Net Income (TTM)
$3.14B
Profit Margin (TTM)
28.4%
EPS (TTM)
$8.71
Free Cash Flow (TTM)
$2.62B
Total Assets
$20.88B
Total Liabilities
$2.58B
Total Equity
$18.17B
Cash & Equivalents
$2.76B
Short-term Investments
$2.46B
Total Liquid Assets
$5.22B
Inventory
$2.03B
Receivables
$1.77B
Net PPE
$5.55B
Goodwill
$580.6M
Intangibles
$778.6M
Current Ratio
4.96
Working Capital
$7.62B
Tangible Book Value
$17.39B
Book Value per Share
$51.34
OCF Q2'26
$1,061.0M
CapEx Q2'26
$112.6M
Free Cash Flow Q2'26
$948.4M
Stock Buybacks Q2'26
$320.3M
Total Buybacks (5 Qtrs)
$3.74B
Diluted Shares Outstanding
357.3M
Return on Equity (ROE)
17.4%
Return on Assets (ROA)
10.5%
Net Profit Margin
28.4%
FCF Yield
~1.9%
CapEx % of Revenue
~4%
Stock-Based Compensation
~$800M
Strengths
Concerns
Intuitive Surgical demonstrates exceptional fundamentals with 18.5% YoY revenue growth, 310 bps operating margin expansion, and 24.2% net income growth in the most recent quarter, supported by a razor-and-blade business model driving recurring revenue from instruments and services. The company maintains a fortress balance sheet with $5.22B in liquid assets, zero long-term debt, and a 4.96x current ratio, while returning $3.74B to shareholders through buybacks over five quarters. Despite strong fundamentals and a 39% expected EPS rebound (Forward EPS $12.09 vs TTM $8.71), the stock trades at a premium 45x TTM P/E with weak technicals (below both moving averages), suggesting a HOLD stance for current holders while awaiting technical confirmation for new positions.
Macro: Risk-on macro backdrop driven by September 2026 jobs report miss: Treasury yields eased, Dow/S&P 500/Nasdaq rallied with tech leading, and Fed-hike expectations faded. Prediction markets price near-term Fed cuts at near-zero (Oct 1%, Dec 4%, Jan 6%) with first meaningful easing not until Apr–Jul 2027 (38–58%). US recession odds at 8% ($2.24M Polymarket volume) support soft-landing consensus. Primary macro risk: Iran war driving broader inflation (not just oil), which could re-anchor yields and undercut the equity rally. FRED data unavailable; qualitative picture from news and prediction markets only.